Table 1.

Summary statistics of the study sample

Baseline CharacteristicsSummary Statistics
Stable/Decline (n=45)Decline/Stable (n=29)All 74 Patients
Age at randomization (yr)53.1 (45.6, 57.8)54.9 (44.5, 62.1)53.7 (45.5, 58.9)
Women13 (28.9)12 (41.4)25 (33)
Baseline eGFR (ml/min per 1.73 m2)a49.7 (41.1, 57.3)60.6 (55.4, 68.0)55.8 (44.1, 61.8)
Baseline urine protein-to-creatinine ratio (g/g)0.05 (0.02, 0.12)0.05 (0.03, 0.11)0.05 (0.02, 0.11)
Duration of stable periods (mo)51 (41, 57)49 (41, 58)50 (41, 58)
Duration of decline periods (mo)34 (24, 50)28 (24, 41)32 (24, 42)
AASK randomized intervention: mean arterial pressure goal
 ≤92 mmHg18 (40)14 (48.3)32 (43)
 102–107 mmHg27 (60)15 (51.7)42 (57)
AASK randomized intervention: antihypertensive drugsb
 Ramipril19 (42.2)10 (34.5)29 (39)
 Metoprolol18 (40)11 (37.9)29 (39)
 Amlodipine8 (17.8)8 (27.6)16 (22)
Average eGFR on segments of estimated trajectory (ml/min per 1.73 m2)
 On stable periods53.6 (46.3, 61.6)39.1 (28.4, 46.2)48.5 (37.2, 58.0)
 On decline periods34.7 (29.5, 52.8)52.6 (44.0, 59.8)43.1 (31.8, 54.8)
  • Continuous variables were summarized by median (25th and 75th percentiles). Categorical variables were summarized by number (percentage).

  • a Averaged over two baseline values, <3 months apart.

  • b The randomized antihypertensive drugs were allocated in 2:2:1 ratio. Amlodipine was stopped 3 years after randomization.